Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets

Fig. 4

Identification of actionable genomic alterations (GAs) in Chinese patients with ampullary adenocarcinoma (AMPAC). (A) Prevalence of clinically actionable GAs and those classified as level 3. (B) Table presenting the approved and clinical trial data of matched therapies for level 3 GAs in AMPAC, pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and colorectal cancer (CRC).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us